secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0000950170-24-023088
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT reports FY2023 net loss $100.8M; positive 4D-150 wet AMD data, Phase 3 plan Q1 2025
--------------------------------------------------------------------------------

- Net loss $100.8M in 2023; cash $299M at Dec 2023; Feb 2024 offering $281M net; runway into H1 2027.
- 4D-150 interim data in wet AMD: favorable safety, no significant inflammation; 24-week data reduced treatment burden vs aflibercept.
- Phase 3 trial for 4D-150 in wet AMD expected to start Q1 2025; FDA RMAT and EMA PRIME designations.
- Pipeline progress: 4D-710 CF positive interim data; 4D-310 Fabry cardiac improvements; IND for 4D-175 GA expected Q2 2024.
- Strategic partnerships: Astellas (up to $942.5M milestones) for ophthalmic vectors; Arbor for CNS gene editing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017024023088/0000950170-24-023088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017024023088/fdmt-20240229.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-023088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer